News

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO)

November 16, 2017

NEW YORK , Nov. 16, 2017 (GLOBE NEWSWIRE)

Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that data from the Phase 2 trial of SL-701 in patients with second-line glioblastoma (GBM)

  Download the PDF Version

Stemline Therapeutics Reports Third Quarter 2017 Financial Results

November 9, 2017

NEW YORK , Nov. 09, 2017 (GLOBE NEWSWIRE)

Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended September 30, 2017.

  Download the PDF Version

Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting

November 1, 2017

NEW YORK , Nov. 01, 2017 (GLOBE NEWSWIRE)

Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in four presentations at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2017 in Atlanta, GA. The full abstracts are now available on the ASH conference website.

  Download the PDF Version

Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint

October 31, 2017

NEW YORK, Oct. 31, 2017 (GLOBE NEWSWIRE)

Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today that the pivotal Phase 2 trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has met its primary endpoint. Based on feedback from the U.S. Food and Drug Administration (FDA), Stemline remains on track to begin submission of its Biologics License Application (BLA) in the 4Q17-1Q18 timeframe.

  Download the PDF Version

Stemline Therapeutics to Present at Upcoming Investor Conferences

September 20, 2017

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE)

Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D., Stemline’s CEO, will be presenting at two upcoming investor conferences.

   Download the PDF Version

Events: Featured & Upcoming

June 8, 2017
Jefferies 2017 Healthcare Conference

 

LISTEN TO THE WEBCAST


September 12, 2017
Corporate Presentation – September 2017

 

VIEW PRESENTATION


September 25, 2017
Cantor Fitzgerald Global Healthcare Conference

 

LISTEN TO THE WEBCAST


September 26, 2017
Ladenburg Thalmann 2017 Healthcare Conference

 

LISTEN TO THE WEBCAST


October 12, 2017
Corporate Presentation – October 2017

 

VIEW PRESENTATION


October 31, 2017
Stemline Therapeutics Update Call

 

VIEW PRESENTATION


Archived Events

June 8, 2017
Jefferies 2017 Healthcare Conference

 

LISTEN TO THE WEBCAST


September 12, 2017
Corporate Presentation – September 2017

 

VIEW PRESENTATION


September 25, 2017
Cantor Fitzgerald Global Healthcare Conference

 

LISTEN TO THE WEBCAST


September 26, 2017
Ladenburg Thalmann 2017 Healthcare Conference

 

LISTEN TO THE WEBCAST